Sixteen patients with surgically removed pancreatic cancer received a vaccine that existed nowhere in the world until their own tumors were sequenced. For eight of them, the shot triggered an immune ...

A recent review from Japan has outlined how regulatory T cell therapies, including chimeric antigen receptor-engineered and gene-edited universal cell products, could help to induce donor-specific ...

David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue ...

Interaction between LFA-1 on natural killer cells and GBP-130 on infected erythrocytes enables immune recognition and killing of Plasmodium falciparum-infected red blood cells.

Luke Pase and Prof. Fujiwara discuss how new targeting strategies and scalable manufacturing approaches are advancing ...

Twelve people whose stomach or colon cancers had defeated every available treatment were infused with their own immune cells, ...

Qihan Biotech receives US FDA’s IND clearance for a universal dual-target CAR-T candidate, QT-019C: Hangzhou, China Friday, May 22, 2026, 12:00 Hrs [IST] Qihan Biotech, a clinic ...

Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, today announced the introduction of G-Linktm, a first-in-class modular ...

Introduction Respiratory syncytial virus (RSV) is the leading cause of severe lower respiratory tract infection in infants globally. Newborns, especially those born prematurely, are at increased risk ...

Presented improved editing data in non-human primates (NHP) for sickle cell disease (SCD), demonstrating a single dose of Gene Writer achieved an average of 85% of long-term hematopoietic stem cells ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients ...